Expo West reflections: post-recession buy-outs and GMP compliance

Private equity firms came in droves to Expo West looking for post-recession bargains, with dietary supplements firm in their sights. A NutraIngredients-USA.com straw poll in the supplements aisles confirmed acquisition offers were as abundant as natural and organic product launches.

Shane Starling sat down with Frank Jaksch, the president and CEO of California-based third party testing company, Chromadex, to assess the ramifications of this kind of consolidation.

When Good Manufacturing Practices (GMP) – which smaller players are due to comply with this June – are thrown into the equation, Jaksch expects a more concentrated market with less products, and less complicated products.

Jaksch also offers tips to meet GMP demands and reduce compliance costs.

Related Topics

Suppliers

Related news

FDA highlights GMP no-no’s

The Food and Drug Administration’s commitment to greater transparency is bearing fruit in the dietary supplements area, with the availability of GMP 483 reports providing valuable insights into potential GMP pitfalls.

The devil in GMP details

In the fifth and final installment of this DSHEA special, Frank Jaksch, the president and chief executive officer of Californian-based botanicals reference provider, Chromadex, outlines why he thinks current GMP inspection methodologies are unlikely to...

2009 trends: the arrival of GMPs

As the old year draws to a close, we review the significant waypoints of 2009 and look ahead to what is likely to dominate next year’s news. Join us now for a whistle-stop tour of the news topics that made the headlines on our flagship food and nutrition...